A Phase 1, Randomized, Open-label, Single-center, Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults in a Nonendemic Region

Trial Profile

A Phase 1, Randomized, Open-label, Single-center, Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults in a Nonendemic Region

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs TDENV LAV (Primary) ; TDENV PIV (Primary)
  • Indications Dengue
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
    • 12 Oct 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
    • 12 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top